BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, Fenga C, Spandidos DΑ, Libra M, Tsatsakis AM. Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). Int J Oncol 2016;48:869-85. [PMID: 26698230 DOI: 10.3892/ijo.2015.3306] [Cited by in Crossref: 186] [Cited by in F6Publishing: 203] [Article Influence: 26.6] [Reference Citation Analysis]
Number Citing Articles
1 Widyananda MH, Puspitarini S, Rohim A, Khairunnisa FA, Jatmiko YD, Masruri M, Widodo N. Anticancer potential of turmeric (Curcuma longa) ethanol extract and prediction of its mechanism through the Akt1 pathway. F1000Res 2022;11:1000. [DOI: 10.12688/f1000research.75735.1] [Reference Citation Analysis]
2 Toson B, Fortes IS, Roesler R, Andrade SF. Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials. Pharmacol Res 2022;183:106403. [PMID: 35987481 DOI: 10.1016/j.phrs.2022.106403] [Reference Citation Analysis]
3 Zhu C, Luo X, Tian T, Rao Z, Wang H, Zhou Z, Mi T, Chen D, Xu Y, Wu Y, Che J, Zhou Y, Li J, Dong X. Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader. European Journal of Medicinal Chemistry 2022;238:114459. [DOI: 10.1016/j.ejmech.2022.114459] [Reference Citation Analysis]
4 George B, Gui B, Raguraman R, Paul AM, Nakshatri H, Pillai MR, Kumar R. AKT1 Transcriptomic Landscape in Breast Cancer Cells. Cells 2022;11:2290. [PMID: 35892586 DOI: 10.3390/cells11152290] [Reference Citation Analysis]
5 Du K, Yang C, Zhou Z, Ma Y, Tian Y, Zhang R, Zhang H, Jiang X, Zhu H, Liu H, Chen P, Liu Y. A Novel Isaindigotone Derivative Displays Better Anti-Proliferation Activities and Induces Apoptosis in Gastric Cancer Cells. IJMS 2022;23:8028. [DOI: 10.3390/ijms23148028] [Reference Citation Analysis]
6 Roman M, Hwang E, Sweet-Cordero EA. Synthetic Vulnerabilities in the KRAS Pathway. Cancers (Basel) 2022;14:2837. [PMID: 35740503 DOI: 10.3390/cancers14122837] [Reference Citation Analysis]
7 Somade OT, Adeyi OE, Ajayi BO, Asunde OO, Iloh PD, Adesanya AA, Babalola OI, Folorunsho OT, Olakunle DA, Lawal OF. Syringic and ascorbic acids prevent NDMA-induced pulmonary fibrogenesis, inflammation, apoptosis, and oxidative stress through the regulation of PI3K-Akt/PKB-mTOR-PTEN signaling pathway. Metabolism Open 2022;14:100179. [DOI: 10.1016/j.metop.2022.100179] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Cho H, Abshire ET, Popp MW, Pröschel C, Schwartz JL, Yeo GW, Maquat LE. AKT constitutes a signal-promoted alternative exon-junction complex that regulates nonsense-mediated mRNA decay. Molecular Cell 2022. [DOI: 10.1016/j.molcel.2022.05.013] [Reference Citation Analysis]
9 Xu Z, Chu M. Advances in Immunosuppressive Agents Based on Signal Pathway. Front Pharmacol 2022;13:917162. [DOI: 10.3389/fphar.2022.917162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Sandeep Kumar J, Sujeevan Reddy G, Medishetti R, Amirul Hossain K, Thirupataiah B, Edelli J, Dilip Bele S, Kristina Edwin R, Joseph A, Shenoy GG, Mallikarjuna Rao C, Pal M. Ultrasound assisted one-pot synthesis of rosuvastatin based novel azaindole derivatives via coupling-cyclization strategy under Pd/Cu-catalysis: their evaluation as potential cytotoxic agents. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.105857] [Reference Citation Analysis]
11 Savill KMZ, Lee BB, Oeh J, Lin J, Lin E, Chung WJ, Young A, Chen W, Miś M, Mesh K, Eastham J, Gnad F, Jiang Z, Stawiski EW, Haley B, Daemen A, Wang X, Koeppen H, Modrusan Z, Martin SE, Sampath D, Lin K. Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors. Nat Commun 2022;13:2057. [PMID: 35440108 DOI: 10.1038/s41467-022-29655-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Algharib AS, Shanab GM, Abdel-ghaffar AB, Ismail MA, Mohamed RH. Bithiophene derivative induced apoptosis and suppression of Akt pathway in mouse leukemic model. TUB 2022;44:53-67. [DOI: 10.3233/tub-211538] [Reference Citation Analysis]
13 Sochacka-Ćwikła A, Mączyński M, Regiec A. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 2022;27:2259. [PMID: 35408658 DOI: 10.3390/molecules27072259] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Jabbarzadeh Kaboli P, Luo S, Chen Y, Jomhori M, Imani S, Xiang S, Wu Z, Li M, Shen J, Zhao Y, Wu X, Hin Cho C, Xiao Z. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress. Gene 2022;816:146171. [PMID: 35026293 DOI: 10.1016/j.gene.2021.146171] [Reference Citation Analysis]
15 An J, Peng C, Xie X, Peng F. New Advances in Targeted Therapy of HER2-Negative Breast Cancer. Front Oncol 2022;12:828438. [DOI: 10.3389/fonc.2022.828438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Yu X, Xu J, Shen Y, Cahuzac KM, Park KS, Dale B, Liu J, Parsons RE, Jin J. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies. J Med Chem 2022. [PMID: 35119851 DOI: 10.1021/acs.jmedchem.1c02165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 Shih PC. The role of the STAT3 signaling transduction pathways in radioresistance. Pharmacol Ther 2022;234:108118. [PMID: 35085605 DOI: 10.1016/j.pharmthera.2022.108118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Iancu G, Serban D, Badiu CD, Tanasescu C, Tudosie MS, Tudor C, Costea DO, Zgura A, Iancu R, Vasile D. Tyrosine kinase inhibitors in breast cancer (Review). Exp Ther Med 2022;23:114. [PMID: 34970337 DOI: 10.3892/etm.2021.11037] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Yu X, Xu J, Xie L, Wang L, Shen Y, Cahuzac KM, Chen X, Liu J, Parsons RE, Jin J. Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders. J Med Chem 2021;64:18054-81. [PMID: 34855399 DOI: 10.1021/acs.jmedchem.1c01476] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
20 Mery B, Poulard C, Le Romancer M, Trédan O. Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls? Int J Mol Sci 2021;22:13512. [PMID: 34948307 DOI: 10.3390/ijms222413512] [Reference Citation Analysis]
21 Patra T, Meyer K, Ray RB, Kanda T, Ray R. Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells. Cell Death Dis 2021;12:1073. [PMID: 34759291 DOI: 10.1038/s41419-021-04371-7] [Reference Citation Analysis]
22 Hongwiangchan N, Sriratanasak N, Wichadakul D, Aksorn N, Chamni S, Chanvorachote P. Hydroquinone 5-O-Cinnamoyl Ester of Renieramycin M Suppresses Lung Cancer Stem Cells by Targeting Akt and Destabilizes c-Myc. Pharmaceuticals (Basel) 2021;14:1112. [PMID: 34832894 DOI: 10.3390/ph14111112] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
23 Parkman GL, Foth M, Kircher DA, Holmen SL, McMahon M. The role of PI3'-lipid signalling in melanoma initiation, progression and maintenance. Exp Dermatol 2021. [PMID: 34717019 DOI: 10.1111/exd.14489] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Zaryouh H, De Pauw I, Baysal H, Pauwels P, Peeters M, Vermorken JB, Lardon F, Wouters A. The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy. Front Oncol 2021;11:697967. [PMID: 34568028 DOI: 10.3389/fonc.2021.697967] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
25 Quambusch L, Depta L, Landel I, Lubeck M, Kirschner T, Nabert J, Uhlenbrock N, Weisner J, Kostka M, Levy LM, Schultz-Fademrecht C, Glanemann F, Althoff K, Müller MP, Siveke JT, Rauh D. Cellular model system to dissect the isoform-selectivity of Akt inhibitors. Nat Commun 2021;12:5297. [PMID: 34489430 DOI: 10.1038/s41467-021-25512-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance. Cancers (Basel) 2021;13:4363. [PMID: 34503172 DOI: 10.3390/cancers13174363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
27 Shuaib M, Prajapati KS, Singh AK, Kushwaha PP, Waseem M, Kumar S. Identification of miRNAs and related hub genes associated with the triple negative breast cancer using integrated bioinformatics analysis and in vitro approach. J Biomol Struct Dyn 2021;:1-15. [PMID: 34387138 DOI: 10.1080/07391102.2021.1961869] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Yanes-Díaz J, Palao-Suay R, Aguilar MR, Riestra-Ayora JI, Ferruelo-Alonso A, Rojo Del Olmo L, Vázquez-Lasa B, Sanz-Fernández R, Sánchez-Rodríguez C. Antitumor Activity of Nanoparticles Loaded with PHT-427, a Novel AKT/PDK1 Inhibitor, for the Treatment of Head and Neck Squamous Cell Carcinoma. Pharmaceutics 2021;13:1242. [PMID: 34452203 DOI: 10.3390/pharmaceutics13081242] [Reference Citation Analysis]
29 Roudsari NM, Lashgari NA, Momtaz S, Abaft S, Jamali F, Safaiepour P, Narimisa K, Jackson G, Bishayee A, Rezaei N, Abdolghaffari AH, Bishayee A. Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention. Pharmaceutics 2021;13:1195. [PMID: 34452154 DOI: 10.3390/pharmaceutics13081195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
30 Chesnokov MS, Borhani S, Halasi M, Arbieva Z, Khan I, Gartel AL. FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML. Front Oncol 2021;11:696532. [PMID: 34381718 DOI: 10.3389/fonc.2021.696532] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
31 Wargasetia TL, Ratnawati H, Widodo N, Widyananda MH. Bioinformatics Study of Sea Cucumber Peptides as Antibreast Cancer Through Inhibiting the Activity of Overexpressed Protein (EGFR, PI3K, AKT1, and CDK4). Cancer Inform 2021;20:11769351211031864. [PMID: 34345161 DOI: 10.1177/11769351211031864] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
32 Alcon C, Gómez Tejeda Zañudo J, Albert R, Wagle N, Scaltriti M, Letai A, Samitier J, Montero J. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. Cells 2021;10:1659. [PMID: 34359829 DOI: 10.3390/cells10071659] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
33 Chen Y, Zheng YF, Lin XH, Zhang JP, Lin F, Shi H. Dendrobium mixture attenuates renal damage in rats with diabetic nephropathy by inhibiting the PI3K/Akt/mTOR pathway. Mol Med Rep 2021;24:590. [PMID: 34165163 DOI: 10.3892/mmr.2021.12229] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
34 Wu JH, Limmer AL, Narayanan D, Doan HQ, Simonette RA, Rady PL, Tyring SK. The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth. Clin Exp Dermatol 2021. [PMID: 34115902 DOI: 10.1111/ced.14798] [Reference Citation Analysis]
35 Yin S, Liu L, Brobbey C, Palanisamy V, Ball LE, Olsen SK, Ostrowski MC, Gan W. PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis. Nat Commun 2021;12:3444. [PMID: 34103528 DOI: 10.1038/s41467-021-23833-2] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
36 Laterza MM, Ciaramella V, Facchini BA, Franzese E, Liguori C, De Falco S, Coppola P, Pompella L, Tirino G, Berretta M, Montella L, Facchini G, Ciardiello F, de Vita F. Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells. Cancers (Basel) 2021;13:2339. [PMID: 34066144 DOI: 10.3390/cancers13102339] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Singh V, Kumar K, Purohit D, Verma R, Pandey P, Bhatia S, Malik V, Mittal V, Rahman MH, Albadrani GM, Arafah MW, El-Demerdash FM, Akhtar MF, Saleem A, Kamel M, Najda A, Abdel-Daim MM, Kaushik D. Exploration of therapeutic applicability and different signaling mechanism of various phytopharmacological agents for treatment of breast cancer. Biomed Pharmacother 2021;139:111584. [PMID: 34243623 DOI: 10.1016/j.biopha.2021.111584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
38 Sherekar S, Viswanathan GA. Boolean dynamic modeling of cancer signaling networks: Prognosis, progression, and therapeutics. Comp Sys Onco 2021;1. [DOI: 10.1002/cso2.1017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Schiliro C, Firestein BL. Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation. Cells 2021;10:1056. [PMID: 33946927 DOI: 10.3390/cells10051056] [Cited by in Crossref: 3] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
40 Afify SM, Oo AKK, Hassan G, Seno A, Seno M. How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer. Expert Rev Anticancer Ther 2021;21:605-19. [PMID: 33857392 DOI: 10.1080/14737140.2021.1918001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Wang Z, Liu C. Upregulated hsa_circRNA_100269 inhibits the growth and metastasis of gastric cancer through inactivating PI3K/Akt axis. PLoS One 2021;16:e0250603. [PMID: 33901239 DOI: 10.1371/journal.pone.0250603] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
42 Halder AK, Cordeiro MNDS. AKT Inhibitors: The Road Ahead to Computational Modeling-Guided Discovery. Int J Mol Sci 2021;22:3944. [PMID: 33920446 DOI: 10.3390/ijms22083944] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
43 Wen L, Zhang G, Ren C, Li X, Mok H, Jia M, Wang Y, Chen B, Li K, Cao L, Li C, Xiao W, Lai J, Lin J, Wei G, Li Y, Zhang Y, Chen X, Liao N. Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients. Cancer Manag Res 2021;13:3055-65. [PMID: 33854375 DOI: 10.2147/CMAR.S299624] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
44 Trafalis DT, Sagredou S, Dalezis P, Voura M, Fountoulaki S, Nikoleousakos N, Almpanakis K, Deligiorgi MV, Sarli V. Anticancer Activity of Triazolo-Thiadiazole Derivatives and Inhibition of AKT1 and AKT2 Activation. Pharmaceutics 2021;13:493. [PMID: 33916378 DOI: 10.3390/pharmaceutics13040493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Zhong W, Chebolu S, Darmani NA. Central and peripheral emetic loci contribute to vomiting evoked by the Akt inhibitor MK-2206 in the least shrew model of emesis. Eur J Pharmacol 2021;900:174065. [PMID: 33775646 DOI: 10.1016/j.ejphar.2021.174065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Richter A, Fischer E, Holz C, Schulze J, Lange S, Sekora A, Knuebel G, Henze L, Roolf C, Murua Escobar H, Junghanss C. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia. Int J Mol Sci 2021;22:2771. [PMID: 33803402 DOI: 10.3390/ijms22052771] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
47 Mai J, Peng XD, Tang J, Du T, Chen YH, Wang ZF, Zhang HL, Huang JH, Zhong ZY, Yang D, Li ZL, Huang Y, Feng GK, Zhu XF, Deng R. AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation. Oncogene 2021;40:2422-36. [PMID: 33664452 DOI: 10.1038/s41388-020-01602-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Baghery Saghchy Khorasani A, Pourbagheri-Sigaroodi A, Pirsalehi A, Safaroghli-Azar A, Zali MR, Bashash D. The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions. Eur J Pharmacol 2021;898:173983. [PMID: 33647255 DOI: 10.1016/j.ejphar.2021.173983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
49 Healy FM, Prior IA, MacEwan DJ. The importance of Ras in drug resistance in cancer. Br J Pharmacol 2021. [PMID: 33634485 DOI: 10.1111/bph.15420] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
50 McKenna M, Balasuriya N, Zhong S, Li SS, O'Donoghue P. Phospho-Form Specific Substrates of Protein Kinase B (AKT1). Front Bioeng Biotechnol 2020;8:619252. [PMID: 33614606 DOI: 10.3389/fbioe.2020.619252] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
51 Lazaro G, Kostaras E, Vivanco I. Inhibitors in AKTion: ATP-competitive vs allosteric. Biochem Soc Trans 2020;48:933-43. [PMID: 32453400 DOI: 10.1042/BST20190777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
52 Mroweh M, Roth G, Decaens T, Marche PN, Lerat H, Macek Jílková Z. Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment. Int J Mol Sci 2021;22:1794. [PMID: 33670268 DOI: 10.3390/ijms22041794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
53 Yin S, Liu L, Gan W. The Roles of Post-Translational Modifications on mTOR Signaling. Int J Mol Sci 2021;22:1784. [PMID: 33670113 DOI: 10.3390/ijms22041784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
54 Wu D, Yan Y, Wei T, Ye Z, Xiao Y, Pan Y, Orme JJ, Wang D, Wang L, Ren S, Huang H. An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors. Cell Rep 2021;34:108744. [PMID: 33596421 DOI: 10.1016/j.celrep.2021.108744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
55 Fujimoto Y, Morita TY, Ohashi A, Haeno H, Hakozaki Y, Fujii M, Kashima Y, Kobayashi SS, Mukohara T. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Sci Rep 2020;10:21762. [PMID: 33303839 DOI: 10.1038/s41598-020-78646-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
56 Sarwar A, Wang B, Su Q, Zhang Y. MiRNAs directly targeting the key intermediates of biological pathways in pancreatic cancer. Biochem Pharmacol 2021;189:114357. [PMID: 33279497 DOI: 10.1016/j.bcp.2020.114357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kozlova NI, Morozevich GE, Gevorkian NM, Berman AE. Implication of integrins α3β1 and α5β1 in invasion and anoikis of SK-Mel-147 human melanoma cells: non-canonical functions of protein kinase Akt. Aging (Albany NY) 2020;12:24345-56. [PMID: 33260159 DOI: 10.18632/aging.202243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Zhu Y, Shi F, Wang M, Ding J. Knockdown of Rab9 Suppresses the Progression of Gastric Cancer Through Regulation of Akt Signaling Pathway. Technol Cancer Res Treat 2020;19:1533033820915958. [PMID: 32301398 DOI: 10.1177/1533033820915958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
59 Starzyńska A, Sejda A, Adamska P, Marvaso G, Sakowicz-Burkiewicz M, Adamski Ł, Jereczek-Fossa BA. Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review. Arch Med Sci 2021;17:207-17. [PMID: 33488873 DOI: 10.5114/aoms.2020.100780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Abdel-Megeed RM, Abd El-Alim SH, Arafa AF, Matloub AA, Farrag AERH, Darwish AB, Abdel-Hamid AZ, Kadry MO. Crosslink among phosphatidylinositol-3 kinase/Akt, PTEN and STAT-5A signaling pathways post liposomal galactomannan hepatocellular carcinoma therapy. Toxicol Rep 2020;7:1531-41. [PMID: 33251120 DOI: 10.1016/j.toxrep.2020.10.018] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
61 Güngör EM, Altıntop MD, Sever B, Çiftçi GA. Design, Synthesis, In vitro and In silico Evaluation of New Hydrazonebased Antitumor Agents as Potent Akt Inhibitors. LDDD 2020;17:1380-92. [DOI: 10.2174/1570180817999200618163507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Noser AA, El-Naggar M, Donia T, Abdelmonsef AH. Synthesis, In Silico and In Vitro Assessment of New Quinazolinones as Anticancer Agents via Potential AKT Inhibition. Molecules 2020;25:E4780. [PMID: 33080996 DOI: 10.3390/molecules25204780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
63 Merckaert T, Zwaenepoel O, Gevaert K, Gettemans J. Development and characterization of protein kinase B/AKT isoform-specific nanobodies. PLoS One 2020;15:e0240554. [PMID: 33045011 DOI: 10.1371/journal.pone.0240554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
64 Wang W, Chen M, Xu H, Lv D, Zhou S, Yang H. USP46 Inhibits Cell Proliferation in Lung Cancer through PHLPP1/AKT Pathway. Biomed Res Int 2020;2020:2509529. [PMID: 33029497 DOI: 10.1155/2020/2509529] [Reference Citation Analysis]
65 Shi J, Liu F, Song Y. Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer. Cancer Manag Res 2020;12:9375-87. [PMID: 33061626 DOI: 10.2147/CMAR.S272685] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
66 Darici S, Alkhaldi H, Horne G, Jørgensen HG, Marmiroli S, Huang X. Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. J Clin Med 2020;9:E2934. [PMID: 32932888 DOI: 10.3390/jcm9092934] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
67 Liu G, Shi A, Wang N, Li M, He X, Yin C, Tu Q, Shen X, Tao Y, Wang Q, Yin H. Polyphenolic Proanthocyanidin-B2 suppresses proliferation of liver cancer cells and hepatocellular carcinogenesis through directly binding and inhibiting AKT activity. Redox Biol 2020;37:101701. [PMID: 32863234 DOI: 10.1016/j.redox.2020.101701] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
68 Chu N, Viennet T, Bae H, Salguero A, Boeszoermenyi A, Arthanari H, Cole PA. The structural determinants of PH domain-mediated regulation of Akt revealed by segmental labeling. Elife 2020;9:e59151. [PMID: 32744507 DOI: 10.7554/eLife.59151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
69 Showalter L, Czerniecki BJ, Koski GK. Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells in vitro and suppress tumor growth in vivo. Oncotarget 2020;11:2873-88. [PMID: 32774769 DOI: 10.18632/oncotarget.27556] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
70 Mączka W, Wińska K, Grabarczyk M. One Hundred Faces of Geraniol. Molecules 2020;25:E3303. [PMID: 32708169 DOI: 10.3390/molecules25143303] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
71 Yi G, Li H, Li Y, Zhao F, Ying Z, Liu M, Zhang J, Liu X. The protective effect of soybean protein-derived peptides on apoptosis via the activation of PI3K-AKT and inhibition on apoptosis pathway. Food Sci Nutr 2020;8:4591-600. [PMID: 32884739 DOI: 10.1002/fsn3.1776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
72 Ma B, Guo W, Shan M, Zhang N, Ma B, Sun G. BRCA1 subcellular localization regulated by PI3K signaling pathway in triple-negative breast cancer MDA-MB-231 cells and hormone-sensitive T47D cells. Open Life Sci 2020;15:501-10. [PMID: 33817238 DOI: 10.1515/biol-2020-0054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Liu X, Long MJC, Hopkins BD, Luo C, Wang L, Aye Y. Precision Targeting of pten-Null Triple-Negative Breast Tumors Guided by Electrophilic Metabolite Sensing. ACS Cent Sci 2020;6:892-902. [PMID: 32607436 DOI: 10.1021/acscentsci.9b00893] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
74 Zhao J, Liu J, Wu N, Zhang H, Zhang S, Li L, Wang M. ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer. Oncol Lett 2020;20:2499-505. [PMID: 32782569 DOI: 10.3892/ol.2020.11768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
75 Waseem D, Khan GM, Haq IU, Rashid U, Syed DN. The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. Toxicol Appl Pharmacol 2020;401:115091. [PMID: 32525019 DOI: 10.1016/j.taap.2020.115091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Vaidya A, Jain S, Sahu S, Jain PK, Pathak K, Pathak D, Kumar R, Jain SK. Anticancer Agents Based on Vulnerable Components in a Signalling Pathway. MRMC 2020;20:886-907. [DOI: 10.2174/1389557520666200212105417] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
77 Maoz A, Ciccone MA, Matsuzaki S, Coleman RL, Matsuo K. Emerging serine-threonine kinase inhibitors for treating ovarian cancer. Expert Opin Emerg Drugs 2019;24:239-53. [PMID: 31755325 DOI: 10.1080/14728214.2019.1696773] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
78 Chen K, Shang Z, Dai AL, Dai PL. Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene. Life Sci 2020;255:117816. [PMID: 32454155 DOI: 10.1016/j.lfs.2020.117816] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
79 Kostaras E, Kaserer T, Lazaro G, Heuss SF, Hussain A, Casado P, Hayes A, Yandim C, Palaskas N, Yu Y, Schwartz B, Raynaud F, Chung YL, Cutillas PR, Vivanco I. A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity. Br J Cancer 2020;123:542-55. [PMID: 32439931 DOI: 10.1038/s41416-020-0889-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
80 Uko NE, Güner OF, Matesic DF, Bowen JP. Akt Pathway Inhibitors. CTMC 2020;20:883-900. [DOI: 10.2174/1568026620666200224101808] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
81 Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, Nitulescu G, Ion GND, Spandidos DA, Nikolouzakis TK, Drakoulis N, Tsatsakis A. Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review). Int J Mol Med 2020;46:467-88. [PMID: 32468014 DOI: 10.3892/ijmm.2020.4608] [Cited by in Crossref: 46] [Cited by in F6Publishing: 77] [Article Influence: 23.0] [Reference Citation Analysis]
82 Jabbarzadeh Kaboli P, Salimian F, Aghapour S, Xiang S, Zhao Q, Li M, Wu X, Du F, Zhao Y, Shen J, Cho CH, Xiao Z. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy. Pharmacol Res 2020;156:104806. [PMID: 32294525 DOI: 10.1016/j.phrs.2020.104806] [Cited by in Crossref: 18] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
83 Landel I, Quambusch L, Depta L, Rauh D. Spotlight on AKT: Current Therapeutic Challenges. ACS Med Chem Lett 2020;11:225-7. [PMID: 32184947 DOI: 10.1021/acsmedchemlett.9b00548] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
84 Abo-Salem HM, Gibriel AA, El Awady ME, Mandour AH. Synthesis, Molecular Docking and Biological Evaluation of Novel Flavone Derivatives as Potential Anticancer Agents Targeting Akt. Med Chem 2021;17:158-70. [PMID: 32141421 DOI: 10.2174/1573406416666200306115035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
85 Borhani S, Gartel AL. FOXM1: a potential therapeutic target in human solid cancers. Expert Opin Ther Targets 2020;24:205-17. [PMID: 32067537 DOI: 10.1080/14728222.2020.1727888] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
86 Jaglanian A, Tsiani E. Rosemary Extract Inhibits Proliferation, Survival, Akt, and mTOR Signaling in Triple-Negative Breast Cancer Cells. Int J Mol Sci 2020;21:E810. [PMID: 32012648 DOI: 10.3390/ijms21030810] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
87 Abdeldayem A, Raouf YS, Constantinescu SN, Moriggl R, Gunning PT. Advances in covalent kinase inhibitors. Chem Soc Rev 2020;49:2617-87. [DOI: 10.1039/c9cs00720b] [Cited by in Crossref: 46] [Cited by in F6Publishing: 68] [Article Influence: 23.0] [Reference Citation Analysis]
88 Gu X, Wang Y, Wang M, Wang J, Li N. Computational investigation of imidazopyridine analogs as protein kinase B (Akt1) allosteric inhibitors by using 3D-QSAR, molecular docking and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics 2021;39:63-78. [DOI: 10.1080/07391102.2019.1705185] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
89 Abdel-wahab AF, Mahmoud W, Al-harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacological Research 2019;150:104511. [DOI: 10.1016/j.phrs.2019.104511] [Cited by in Crossref: 80] [Cited by in F6Publishing: 89] [Article Influence: 26.7] [Reference Citation Analysis]
90 Thirumal Kumar D, Jain N, Evangeline J, Kamaraj B, Siva R, Zayed H, George Priya Doss C. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer. Computers in Biology and Medicine 2019;115:103513. [DOI: 10.1016/j.compbiomed.2019.103513] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
91 Hinz N, Jücker M. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Commun Signal 2019;17:154. [PMID: 31752925 DOI: 10.1186/s12964-019-0450-3] [Cited by in Crossref: 60] [Cited by in F6Publishing: 91] [Article Influence: 20.0] [Reference Citation Analysis]
92 Javadinia SA, Shahidsales S, Fanipakdel A, Mostafapour A, Joudi-Mashhad M, Ferns GA, Avan A. The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy. Curr Pharm Des 2018;24:4646-51. [PMID: 30636576 DOI: 10.2174/1381612825666190110143258] [Cited by in Crossref: 13] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
93 Gehringer F, Weissinger SE, Möller P, Wirth T, Ushmorov A. Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma. Leukemia 2020;34:857-71. [PMID: 31719683 DOI: 10.1038/s41375-019-0628-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
94 Ayoup MS, Fouad MA, Abdel-Hamid H, Ramadan ES, Abu-Serie MM, Noby A, Teleb M. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis. Eur J Med Chem 2020;186:111875. [PMID: 31740054 DOI: 10.1016/j.ejmech.2019.111875] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
95 Wu D, Wang Z, Lin M, Shang Y, Wang F, Zhou J, Wang F, Zhang X, Luo X, Huang W. In Vitro and In Vivo Antitumor Activity of Cucurbitacin C, a Novel Natural Product From Cucumber. Front Pharmacol 2019;10:1287. [PMID: 31780930 DOI: 10.3389/fphar.2019.01287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
96 Quambusch L, Landel I, Depta L, Weisner J, Uhlenbrock N, Müller MP, Glanemann F, Althoff K, Siveke JT, Rauh D. Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity. Angew Chem 2019;131:18999-9005. [DOI: 10.1002/ange.201909857] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
97 Quambusch L, Landel I, Depta L, Weisner J, Uhlenbrock N, Müller MP, Glanemann F, Althoff K, Siveke JT, Rauh D. Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity. Angew Chem Int Ed Engl 2019;58:18823-9. [PMID: 31584233 DOI: 10.1002/anie.201909857] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 6.7] [Reference Citation Analysis]
98 Asare-Werehene M, Nakka K, Reunov A, Chiu CT, Lee WT, Abedini MR, Wang PW, Shieh DB, Dilworth FJ, Carmona E, Le T, Mes-Masson AM, Burger D, Tsang BK. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Oncogene 2020;39:1600-16. [PMID: 31700155 DOI: 10.1038/s41388-019-1087-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 33] [Article Influence: 7.7] [Reference Citation Analysis]
99 Li YL, Weng HC, Hsu JL, Lin SW, Guh JH, Hsu LC. The Combination of MK-2206 and WZB117 Exerts a Synergistic Cytotoxic Effect Against Breast Cancer Cells. Front Pharmacol 2019;10:1311. [PMID: 31780937 DOI: 10.3389/fphar.2019.01311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
100 Rizk M, Rizq O, Oshima M, Nakajima-Takagi Y, Koide S, Saraya A, Isshiki Y, Chiba T, Yamazaki S, Ma A, Jin J, Iwama A, Mimura N. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma. Cancer Sci 2019;110:3695-707. [PMID: 31571328 DOI: 10.1111/cas.14207] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
101 Robert G, Jacquel A, Auberger P. Chaperone-Mediated Autophagy and Its Emerging Role in Hematological Malignancies. Cells 2019;8:E1260. [PMID: 31623164 DOI: 10.3390/cells8101260] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
102 Jiao Y, Shen F, Wang Z, Ye L, Zhang M, Gao J, Hou Y, Bai G. Genipin, a natural AKT inhibitor, targets the PH domain to affect downstream signaling and alleviates inflammation. Biochem Pharmacol 2019;170:113660. [PMID: 31605673 DOI: 10.1016/j.bcp.2019.113660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
103 Razaghi A, Heimann K, Schaeffer PM, Gibson SB. Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies. Apoptosis 2018;23:93-112. [PMID: 29322476 DOI: 10.1007/s10495-018-1440-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
104 Bougen-Zhukov N, Nouri Y, Godwin T, Taylor M, Hakkaart C, Single A, Brew T, Permina E, Chen A, Black MA, Guilford P. Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells. Cancers (Basel) 2019;11:E1359. [PMID: 31540244 DOI: 10.3390/cancers11091359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
105 Guo K, Tang W, Zhuo H, Zhao G. Recent Advance of Akt Inhibitors in Clinical Trials. ChemistrySelect 2019;4:9040-4. [DOI: 10.1002/slct.201901293] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
106 Sharma V, Sharma AK, Punj V, Priya P. Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer. Semin Cancer Biol 2019;59:133-46. [PMID: 31408722 DOI: 10.1016/j.semcancer.2019.08.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
107 Li Z, Zhang Y, Wang R, Zou K, Zou L. Genetic alterations in anaplastic thyroid carcinoma and targeted therapies. Exp Ther Med 2019;18:2369-77. [PMID: 31555347 DOI: 10.3892/etm.2019.7869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
108 Iacano AJ, Lewis H, Hazen JE, Andro H, Smith JD, Gulshan K. Miltefosine increases macrophage cholesterol release and inhibits NLRP3-inflammasome assembly and IL-1β release. Sci Rep 2019;9:11128. [PMID: 31366948 DOI: 10.1038/s41598-019-47610-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
109 Zeng RJ, Zheng CW, Gu JE, Zhang HX, Xie L, Xu LY, Li EM. RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes. Mol Oncol 2019;13:2010-30. [PMID: 31314174 DOI: 10.1002/1878-0261.12548] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
110 Gener P, Rafael D, Seras-Franzoso J, Perez A, Pindado LA, Casas G, Arango D, Fernández Y, Díaz-Riascos ZV, Abasolo I, Schwartz S Jr. Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells. Cancers (Basel) 2019;11:E1058. [PMID: 31357505 DOI: 10.3390/cancers11081058] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
111 Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. Semin Cancer Biol 2019;59:125-32. [PMID: 31323288 DOI: 10.1016/j.semcancer.2019.07.009] [Cited by in Crossref: 105] [Cited by in F6Publishing: 265] [Article Influence: 35.0] [Reference Citation Analysis]
112 Mitchell KA, Williams H. Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes. Urol Oncol 2019:S1078-1439(19)30157-7. [PMID: 31239186 DOI: 10.1016/j.urolonc.2019.04.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
113 Chandrasekaran B, Pal D, Kolluru V, Tyagi A, Baby B, Dahiya NR, Youssef K, Alatassi H, Ankem MK, Sharma AK, Damodaran C. The chemopreventive effect of withaferin A on spontaneous and inflammation-associated colon carcinogenesis models. Carcinogenesis 2018;39:1537-47. [PMID: 30124785 DOI: 10.1093/carcin/bgy109] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
114 Yue C, Liang C, Ge H, Yan L, Xu Y, Li G, Li P, Wei Z, Wu J. Pseudogene DUXAP10 acts as a diagnostic and prognostic marker and promotes cell proliferation by activating PI3K/AKT pathway in hepatocellular carcinoma. Onco Targets Ther 2019;12:4555-66. [PMID: 31354289 DOI: 10.2147/OTT.S210623] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
115 Revathidevi S, Munirajan AK. Akt in cancer: Mediator and more. Semin Cancer Biol 2019;59:80-91. [PMID: 31173856 DOI: 10.1016/j.semcancer.2019.06.002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 154] [Article Influence: 25.3] [Reference Citation Analysis]
116 Yang X, Zhang X, Liu Y, Xi T, Xiong J. Insulin transcriptionally down-regulates carboxylesterases through pregnane X receptor in an Akt-dependent manner. Toxicology 2019;422:60-8. [DOI: 10.1016/j.tox.2019.04.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
117 Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, Boucher KM, McMahon M, Davies MA, Mendoza MC, VanBrocklin MW, Holmen SL. AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis. Mol Cancer Res 2019;17:1787-800. [PMID: 31138602 DOI: 10.1158/1541-7786.MCR-18-1372] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
118 Liu L, Zhang L, Zhao S, Zhao XY, Min PX, Ma YD, Wang YY, Chen Y, Tang SJ, Zhang YJ, Du J, Gu L. Non-canonical Notch Signaling Regulates Actin Remodeling in Cell Migration by Activating PI3K/AKT/Cdc42 Pathway. Front Pharmacol 2019;10:370. [PMID: 31057403 DOI: 10.3389/fphar.2019.00370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
119 Akalin Çiftçi G, Sever B, Altintop MD. Comprehensive Study on Thiadiazole-Based Anticancer Agents Inducing Cell Cycle Arrest and Apoptosis/Necrosis Through Suppression of Akt Activity in Lung Adenocarcinoma and Glioma Cells. Turk J Pharm Sci 2019;16:119-31. [PMID: 32454705 DOI: 10.4274/tjps.galenos.2019.2018.96658] [Reference Citation Analysis]
120 Mota MSV, Jackson WP, Bailey SK, Vayalil P, Landar A, Rostas JW 3rd, Mulekar MS, Samant RS, Shevde LA. Deficiency of tumor suppressor Merlin facilitates metabolic adaptation by co-operative engagement of SMAD-Hippo signaling in breast cancer. Carcinogenesis 2018;39:1165-75. [PMID: 29893810 DOI: 10.1093/carcin/bgy078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
121 Wu K, Yin X, Jin Y, Liu F, Gao J. Identification of aberrantly methylated differentially expressed genes in prostate carcinoma using integrated bioinformatics. Cancer Cell Int 2019;19:51. [PMID: 30872976 DOI: 10.1186/s12935-019-0763-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
122 Zanini CTP, Müller P, Ji Y, Quintana FA. A Bayesian random partition model for sequential refinement and coagulation. Biometrics 2019;75:988-99. [PMID: 30820945 DOI: 10.1111/biom.13047] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Zhang Y, Luo YH, Piao XJ, Shen GN, Wang JR, Feng YC, Li JQ, Xu WT, Zhang Y, Zhang T, Wang CY, Jin CH. The design of 1,4-naphthoquinone derivatives and mechanisms underlying apoptosis induction through ROS-dependent MAPK/Akt/STAT3 pathways in human lung cancer cells. Bioorg Med Chem 2019;27:1577-87. [PMID: 30846406 DOI: 10.1016/j.bmc.2019.03.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
124 Nani A, Belarbi M, Murtaza B, Benammar C, Merghoub T, Rialland M, Akhtar Khan N, Hichami A. Polyphenols from Pennisetum glaucum grains induce MAP kinase phosphorylation and cell cycle arrest in human osteosarcoma cells. Journal of Functional Foods 2019;54:422-32. [DOI: 10.1016/j.jff.2019.01.042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
125 Lee KT, Vider J, Tang JC, Gopalan V, Lam AK. GAEC1 drives colon cancer progression: LEE et al.. Mol Carcinog 2019;58:1145-54. [DOI: 10.1002/mc.22998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
126 Uhlenbrock N, Smith S, Weisner J, Landel I, Lindemann M, Le TA, Hardick J, Gontla R, Scheinpflug R, Czodrowski P, Janning P, Depta L, Quambusch L, Müller MP, Engels B, Rauh D. Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt. Chem Sci 2019;10:3573-85. [PMID: 30996949 DOI: 10.1039/c8sc05212c] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
127 Villafañez F, García IA, Carbajosa S, Pansa MF, Mansilla S, Llorens MC, Angiolini V, Guantay L, Jacobs H, Madauss KP, Gloger I, Gottifredi V, Bocco JL, Soria G. AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress. Oncogene 2019;38:4310-24. [PMID: 30705406 DOI: 10.1038/s41388-019-0724-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
128 Chen PJ, Ko IL, Lee CL, Hu HC, Chang FR, Wu YC, Leu YL, Wu CC, Lin CY, Pan CY, Tsai YF, Hwang TL. Targeting allosteric site of AKT by 5,7-dimethoxy-1,4-phenanthrenequinone suppresses neutrophilic inflammation. EBioMedicine 2019;40:528-40. [PMID: 30709770 DOI: 10.1016/j.ebiom.2019.01.043] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
129 Liu L, Fan S, Li W, Tao W, Shi T, Zhao YL. Theoretical Investigation of the Structural Characteristics in the Active State of Akt1 Kinase. J Chem Inf Model 2019;59:316-25. [PMID: 30571108 DOI: 10.1021/acs.jcim.8b00506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
130 Ochoa R, Rocha-Roa C, Marín-Villa M, Robledo SM, Varela-M RE. Search of Allosteric Inhibitors and Associated Proteins of an AKT-like Kinase from Trypanosoma cruzi. Int J Mol Sci 2018;19:E3951. [PMID: 30544836 DOI: 10.3390/ijms19123951] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
131 Li W, Hou JZ, Niu J, Xi ZQ, Ma C, Sun H, Wang CJ, Fang D, Li Q, Xie SQ. Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated β-catenin nuclear accumulation. Cell Commun Signal 2018;16:82. [PMID: 30445978 DOI: 10.1186/s12964-018-0295-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
132 Nandan D, Zhang N, Yu Y, Schwartz B, Chen S, Kima PE, Reiner NE. Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania. PLoS One 2018;13:e0206920. [PMID: 30399177 DOI: 10.1371/journal.pone.0206920] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
133 Chatterjee B, Ghosh K, Suresh L, Kanade SR. Curcumin ameliorates PRMT5-MEP50 arginine methyltransferase expression by decreasing the Sp1 and NF-YA transcription factors in the A549 and MCF-7 cells. Mol Cell Biochem 2019;455:73-90. [PMID: 30392062 DOI: 10.1007/s11010-018-3471-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
134 Al-Saffar NMS, Troy H, Wong Te Fong AC, Paravati R, Jackson LE, Gowan S, Boult JKR, Robinson SP, Eccles SA, Yap TA, Leach MO, Chung YL. Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma. Br J Cancer 2018;119:1118-28. [PMID: 30377337 DOI: 10.1038/s41416-018-0242-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
135 Nitulescu GM, Van De Venter M, Nitulescu G, Ungurianu A, Juzenas P, Peng Q, Olaru OT, Grădinaru D, Tsatsakis A, Tsoukalas D, Spandidos DA, Margina D. The Akt pathway in oncology therapy and beyond (Review). Int J Oncol 2018;53:2319-31. [PMID: 30334567 DOI: 10.3892/ijo.2018.4597] [Cited by in Crossref: 34] [Cited by in F6Publishing: 97] [Article Influence: 8.5] [Reference Citation Analysis]
136 Samadi P, Saki S, Dermani FK, Pourjafar M, Saidijam M. Emerging ways to treat breast cancer: will promises be met? Cell Oncol (Dordr) 2018;41:605-21. [PMID: 30259416 DOI: 10.1007/s13402-018-0409-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
137 Balasuriya N, McKenna M, Liu X, Li SSC, O'Donoghue P. Phosphorylation-Dependent Inhibition of Akt1. Genes (Basel) 2018;9:E450. [PMID: 30205513 DOI: 10.3390/genes9090450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
138 McKenna M, McGarrigle S, Pidgeon GP. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. Biochim Biophys Acta Rev Cancer. 2018;1870:185-197. [PMID: 30318472 DOI: 10.1016/j.bbcan.2018.08.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
139 Wang J, Chen Y, Mo PL, Wei YJ, Liu KC, Zhang ZG, Zhang ZW, Chen XP, Zhang L. 1α,25-Dihydroxyvitamin D3 inhibits aflatoxin B1-induced proliferation and dedifferentiation of hepatic progenitor cells by regulating PI3K/Akt and Hippo pathways. J Steroid Biochem Mol Biol 2018;183:228-37. [PMID: 30099061 DOI: 10.1016/j.jsbmb.2018.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
140 Warns J, Marwarha G, Freking N, Ghribi O. 27-hydroxycholesterol decreases cell proliferation in colon cancer cell lines. Biochimie 2018;153:171-80. [PMID: 30009860 DOI: 10.1016/j.biochi.2018.07.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
141 Wiedemann B, Weisner J, Rauh D. Chemical modulation of transcription factors. Medchemcomm 2018;9:1249-72. [PMID: 30151079 DOI: 10.1039/c8md00273h] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
142 Bjune K, Sundvold H, Leren TP, Naderi S. MK-2206, an allosteric inhibitor of AKT, stimulates LDLR expression and LDL uptake: A potential hypocholesterolemic agent. Atherosclerosis 2018;276:28-38. [PMID: 30025252 DOI: 10.1016/j.atherosclerosis.2018.07.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
143 Lu Q, He Y, Wang Y, Gao L, Zheng Y, Zhang Z, Cao B, Wang Q, Mao X, Hu S. Saponins From Paris forrestii (Takht.) H. Li Display Potent Activity Against Acute Myeloid Leukemia by Suppressing the RNF6/AKT/mTOR Signaling Pathway. Front Pharmacol 2018;9:673. [PMID: 29997504 DOI: 10.3389/fphar.2018.00673] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
144 Altıntop MD, Sever B, Akalın Çiftçi G, Turan-Zitouni G, Kaplancıklı ZA, Özdemir A. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors. Eur J Med Chem 2018;155:905-24. [PMID: 29966916 DOI: 10.1016/j.ejmech.2018.06.049] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
145 Huang CY, Hung MH, Shih CT, Hsieh FS, Kuo CW, Tsai MH, Chang SS, Hsiao YJ, Chen LJ, Chao TI, Chen KF. Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation. J Pharmacol Exp Ther 2018;366:410-21. [PMID: 29914877 DOI: 10.1124/jpet.118.249102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
146 Altıntop MD, Sever B, Akalın Çiftçi G, Özdemir A. Design, Synthesis, and Evaluation of a New Series of Thiazole-Based Anticancer Agents as Potent Akt Inhibitors. Molecules 2018;23:E1318. [PMID: 29857484 DOI: 10.3390/molecules23061318] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
147 Buetti-Dinh A, Jensen R, Friedman R. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy. BMC Cancer 2018;18:569. [PMID: 29776351 DOI: 10.1186/s12885-018-4451-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
148 Carpi S, Polini B, Poli G, Alcantara Barata G, Fogli S, Romanini A, Tuccinardi T, Guella G, Frontini FP, Nieri P, Di Giuseppe G. Anticancer Activity of Euplotin C, Isolated from the Marine Ciliate Euplotes crassus, Against Human Melanoma Cells. Mar Drugs 2018;16:E166. [PMID: 29772645 DOI: 10.3390/md16050166] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
149 Han HY, Kim HJ, Jeong SH, Kim J, Jeong SH, Kim GC, Hwang DS, Kim UK, Ryu MH. The Flavonoid Jaceosidin from Artemisia princeps Induces Apoptotic Cell Death and Inhibits the Akt Pathway in Oral Cancer Cells. Evid Based Complement Alternat Med 2018;2018:5765047. [PMID: 29861773 DOI: 10.1155/2018/5765047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
150 Gupta N, Duggal S, Kumar A, Saquib NM, Rao KVS. Concurrent interactome and metabolome analysis reveals role of AKT1 in central carbon metabolism. BMC Res Notes 2018;11:270. [PMID: 29720254 DOI: 10.1186/s13104-018-3364-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
151 Jiang P, Sellers WR, Liu XS. Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. Annu Rev Biomed Data Sci 2018;1:1-27. [PMID: 31342013 DOI: 10.1146/annurev-biodatasci-080917-013350] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
152 Yndestad S, Austreid E, Svanberg IR, Knappskog S, Lønning PE, Eikesdal HP. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. Oncotarget 2017;8:41227-41. [PMID: 28476032 DOI: 10.18632/oncotarget.17167] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
153 Kiweler N, Krämer OH. PNUTS at the crossroads of tumorigenesis and metastasis formation. J Thorac Dis 2018;10:560-3. [PMID: 29607112 DOI: 10.21037/jtd.2017.12.135] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
154 Kalal BS, Fathima F, Pai VR, Sanjeev G, Krishna CM, Upadhya D. Inhibition of ERK1/2 or AKT Activity Equally Enhances Radiation Sensitization in B16F10 Cells. World J Oncol 2018;9:21-8. [PMID: 29581812 DOI: 10.14740/wjon1088w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
155 Ranieri C, Di Tommaso S, Loconte DC, Grossi V, Sanese P, Bagnulo R, Susca FC, Forte G, Peserico A, De Luisi A, Bartuli A, Selicorni A, Melis D, Lerone M, Praticò AD, Abbadessa G, Yu Y, Schwartz B, Ruggieri M, Simone C, Resta N. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS). Neurogenetics 2018;19:77-91. [PMID: 29549527 DOI: 10.1007/s10048-018-0540-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 9.8] [Reference Citation Analysis]
156 Lu H, Yang S, Zhu H, Tong X, Xie F, Qin J, Han N, Wu X, Fan Y, Shao YW, Mao W. Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma. BMC Cancer. 2018;18:251. [PMID: 29506494 DOI: 10.1186/s12885-018-4159-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
157 Brolih S, Parks SK, Vial V, Durivault J, Mostosi L, Pouysségur J, Pagès G, Picco V. AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity. BMC Cancer 2018;18:249. [PMID: 29506489 DOI: 10.1186/s12885-018-4169-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
158 Cai S, Cheng X, Liu Y, Lin Z, Zeng W, Yang C, Liu L, Chukwuebuka OA, Li W. EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer. Exp Cell Res 2018;367:37-46. [PMID: 29496520 DOI: 10.1016/j.yexcr.2018.02.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
159 Song Q, Sun X, Guo H, Yu Q. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. Oncotarget 2017;8:5003-15. [PMID: 28002807 DOI: 10.18632/oncotarget.14009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
160 Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy. Mol Cancer 2018;17:37. [PMID: 29455665 DOI: 10.1186/s12943-018-0803-3] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 25.5] [Reference Citation Analysis]
161 Al-Sha'er MA, Taha MO. Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor. J Mol Graph Model 2018;83:153-66. [PMID: 29456101 DOI: 10.1016/j.jmgm.2018.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
162 Bayat M, Nasri S. Synthesis and dynamic 1 H NMR study of pyrazolo substituted pyrrolo[2,3- d ]pyrimidines via a regioselective heterocyclization. Journal of Molecular Structure 2018;1154:366-72. [DOI: 10.1016/j.molstruc.2017.10.056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
163 Alamri AM, Liu X, Blancato JK, Haddad BR, Wang W, Zhong X, Choudhary S, Krawczyk E, Kallakury BV, Davidson BJ, Furth PA. Expanding primary cells from mucoepidermoid and other salivary gland neoplasms for genetic and chemosensitivity testing. Dis Model Mech 2018;11:dmm031716. [PMID: 29419396 DOI: 10.1242/dmm.031716] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
164 Mazzon M, Castro C, Thaa B, Liu L, Mutso M, Liu X, Mahalingam S, Griffin JL, Marsh M, McInerney GM. Alphavirus-induced hyperactivation of PI3K/AKT directs pro-viral metabolic changes. PLoS Pathog 2018;14:e1006835. [PMID: 29377936 DOI: 10.1371/journal.ppat.1006835] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
165 Oh C, Ryoo J, Park K, Kim B, Daly MB, Cho D, Ahn K. A central role for PI3K-AKT signaling pathway in linking SAMHD1-deficiency to the type I interferon signature. Sci Rep 2018;8:84. [PMID: 29311560 DOI: 10.1038/s41598-017-18308-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
166 FitzGerald LM, Zhao S, Leonardson A, Geybels MS, Kolb S, Lin DW, Wright JL, Eeles R, Kote-Jarai Z, Govindasami K, Giles GG, Southey MC, Schleutker J, Tammela TL, Sipeky C, Penney KL, Stampfer MJ, Gronberg H, Wiklund F, Stattin P, Hugosson J, Karyadi DM, Ostrander EA, Feng Z, Stanford JL. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis 2018;21:228-37. [PMID: 29298992 DOI: 10.1038/s41391-017-0029-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
167 Tabrizian K, Khodayari H, Rezaee R, Jahantigh H, Bagheri G, Tsarouhas K, Hashemzaei M. Magnesium sulfate protects the heart against carbon monoxide-induced cardiotoxicity in rats. Res Pharm Sci 2018;13:65-72. [PMID: 29387113 DOI: 10.4103/1735-5362.220969] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
168 Najm FJ, Strand C, Donovan KF, Hegde M, Sanson KR, Vaimberg EW, Sullender ME, Hartenian E, Kalani Z, Fusi N, Listgarten J, Younger ST, Bernstein BE, Root DE, Doench JG. Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens. Nat Biotechnol 2018;36:179-89. [PMID: 29251726 DOI: 10.1038/nbt.4048] [Cited by in Crossref: 126] [Cited by in F6Publishing: 120] [Article Influence: 25.2] [Reference Citation Analysis]
169 Choi M, Shi J, Zhu Y, Yang R, Cho KH. Network dynamics-based cancer panel stratification for systemic prediction of anticancer drug response. Nat Commun 2017;8:1940. [PMID: 29208897 DOI: 10.1038/s41467-017-02160-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
170 García-Aranda M, Téllez T, Muñoz M, Redondo M. Clusterin inhibition mediates sensitivity to chemotherapy and radiotherapy in human cancer. Anticancer Drugs 2017;28:702-16. [PMID: 28471806 DOI: 10.1097/CAD.0000000000000507] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
171 Honardoost M, Rad SMAH. Triangle of AKT2, miRNA, and Tumorigenesis in Different Cancers. Appl Biochem Biotechnol 2018;185:524-40. [DOI: 10.1007/s12010-017-2657-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
172 García-Aranda M, Redondo M. Protein Kinase Targets in Breast Cancer. Int J Mol Sci 2017;18:E2543. [PMID: 29186886 DOI: 10.3390/ijms18122543] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
173 Yao S, Fan LY, Lam EW. The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance. Semin Cancer Biol. 2018;50:77-89. [PMID: 29180117 DOI: 10.1016/j.semcancer.2017.11.018] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 12.6] [Reference Citation Analysis]
174 Yu Y, Hall T, Eathiraj S, Wick MJ, Schwartz B, Abbadessa G. In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor. Anticancer Drugs 2017;28:503-13. [PMID: 28240679 DOI: 10.1097/CAD.0000000000000486] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
175 Tripathi BK, Grant T, Qian X, Zhou M, Mertins P, Wang D, Papageorge AG, Tarasov SG, Hunter KW, Carr SA, Lowy DR. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1. J Cell Biol 2017;216:4255-70. [PMID: 29114068 DOI: 10.1083/jcb.201703105] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
176 He Q, Wang F, Honda T, Lindquist DM, Dillman JR, Timchenko NA, Redington AN. Intravenous miR-144 inhibits tumor growth in diethylnitrosamine-induced hepatocellular carcinoma in mice. Tumour Biol 2017;39:1010428317737729. [PMID: 29072132 DOI: 10.1177/1010428317737729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
177 Wadhwa B, Makhdoomi U, Vishwakarma R, Malik F. Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer. Anticancer Drugs 2017;28:569-80. [PMID: 28379898 DOI: 10.1097/CAD.0000000000000496] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
178 Yang Q, Cui Y, Luo F, Liu X, Wang Q, Bai J, Dong F, Sun Q, Lu L, Xu H, Xue J, Chen C, Xiang Q, Liu Q, Zhang Q. MicroRNA-191, acting via the IRS-1/Akt signaling pathway, is involved in the hepatic insulin resistance induced by cigarette smoke extract. Environ Sci Pollut Res Int 2018;25:22400-7. [PMID: 28963693 DOI: 10.1007/s11356-017-0277-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
179 Yamaji M, Ota A, Wahiduzzaman M, Karnan S, Hyodo T, Konishi H, Tsuzuki S, Hosokawa Y, Haniuda M. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med 2017;6:2646-59. [PMID: 28960945 DOI: 10.1002/cam4.1179] [Cited by in Crossref: 20] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
180 Huang BX, Newcomer K, Kevala K, Barnaeva E, Zheng W, Hu X, Patnaik S, Southall N, Marugan J, Ferrer M, Kim HY. Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt. Sci Rep 2017;7:11673. [PMID: 28916818 DOI: 10.1038/s41598-017-11870-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
181 Malgerud L, Lindberg J, Wirta V, Gustafsson-Liljefors M, Karimi M, Moro CF, Stecker K, Picker A, Huelsewig C, Stein M, Bohnert R, Del Chiaro M, Haas SL, Heuchel RL, Permert J, Maeurer MJ, Brock S, Verbeke CS, Engstrand L, Jackson DB, Grönberg H, Löhr JM. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Mol Oncol 2017;11:1413-29. [PMID: 28675654 DOI: 10.1002/1878-0261.12108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
182 Liu Y, Yin Y, Zhang Z, Li CJ, Zhang H, Zhang D, Jiang C, Nomie K, Zhang L, Wang ML, Zhao G. Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity. Eur J Med Chem 2017;138:543-51. [PMID: 28704757 DOI: 10.1016/j.ejmech.2017.06.067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
183 Ramezani S, Vousooghi N, Ramezani Kapourchali F, Joghataei MT. Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K/AKT pathway in a glioblastoma heterotopic model. Apoptosis 2017;22:1025-34. [DOI: 10.1007/s10495-017-1382-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
184 Leroux AE, Schulze JO, Biondi RM. AGC kinases, mechanisms of regulation ‎and innovative drug development. Semin Cancer Biol 2018;48:1-17. [PMID: 28591657 DOI: 10.1016/j.semcancer.2017.05.011] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 12.0] [Reference Citation Analysis]
185 Guerra ACVA, Soares LAL, Ferreira MRA, Araújo AA, Rocha HAO, Medeiros JS, Cavalcante RDS, Júnior RFA. Libidibia ferrea presents antiproliferative, apoptotic and antioxidant effects in a colorectal cancer cell line. Biomed Pharmacother 2017;92:696-706. [PMID: 28586741 DOI: 10.1016/j.biopha.2017.05.123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
186 Liu S, Cheng C. Akt Signaling Is Sustained by a CD44 Splice Isoform-Mediated Positive Feedback Loop. Cancer Res 2017;77:3791-801. [PMID: 28533273 DOI: 10.1158/0008-5472.CAN-16-2545] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
187 O'Donnell JS, Massi D, Teng MWL, Mandala M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin Cancer Biol 2018;48:91-103. [PMID: 28467889 DOI: 10.1016/j.semcancer.2017.04.015] [Cited by in Crossref: 123] [Cited by in F6Publishing: 126] [Article Influence: 24.6] [Reference Citation Analysis]
188 Ruzzene M, Bertacchini J, Toker A, Marmiroli S. Cross-talk between the CK2 and AKT signaling pathways in cancer. Adv Biol Regul 2017;64:1-8. [PMID: 28373060 DOI: 10.1016/j.jbior.2017.03.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
189 Ríos-Marco P, Marco C, Gálvez X, Jiménez-López JM, Carrasco MP. Alkylphospholipids: An update on molecular mechanisms and clinical relevance. Biochim Biophys Acta Biomembr 2017;1859:1657-67. [PMID: 28238819 DOI: 10.1016/j.bbamem.2017.02.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
190 Serini S, Calviello G. Modulation of Ras/ERK and Phosphoinositide Signaling by Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role in Combination with Targeted Drugs. Nutrients 2017;9:E185. [PMID: 28241486 DOI: 10.3390/nu9030185] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
191 Vuckovic S, Vandyke K, Rickards DA, McCauley Winter P, Brown SHJ, Mitchell TW, Liu J, Lu J, Askenase PW, Yuriev E, Capuano B, Ramsland PA, Hill GR, Zannettino ACW, Hutchinson AT. The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells. Br J Haematol 2017;177:423-40. [PMID: 28211573 DOI: 10.1111/bjh.14561] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
192 Rodgers SJ, Ferguson DT, Mitchell CA, Ooms LM. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases. Biosci Rep 2017;37:BSR20160432. [PMID: 28082369 DOI: 10.1042/BSR20160432] [Cited by in Crossref: 48] [Cited by in F6Publishing: 58] [Article Influence: 9.6] [Reference Citation Analysis]
193 Guerra L, Odorisio T, Zambruno G, Castiglia D. Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma development. Matrix Biol 2017;63:1-10. [PMID: 28126522 DOI: 10.1016/j.matbio.2017.01.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 10.2] [Reference Citation Analysis]
194 Miller MS, Maheshwari S, McRobb FM, Kinzler KW, Amzel LM, Vogelstein B, Gabelli SB. Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design. Bioorg Med Chem 2017;25:1481-6. [PMID: 28129991 DOI: 10.1016/j.bmc.2017.01.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
195 Kim K, Li J, Barazia A, Tseng A, Youn SW, Abbadessa G, Yu Y, Schwartz B, Andrews RK, Gordeuk VR, Cho J. ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease. Haematologica 2017;102:246-59. [PMID: 27758820 DOI: 10.3324/haematol.2016.151159] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
196 Chen X, Calvisi DF. The dark side of the moon: AKT as a tumor suppressor in the liver? Hepatology 2016;64:1358-61. [PMID: 27515381 DOI: 10.1002/hep.28762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
197 Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma. Int J Cancer 2017;140:480-4. [PMID: 27649927 DOI: 10.1002/ijc.30440] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
198 Chatzinikolaidou M. Cell spheroids: the new frontiers in in vitro models for cancer drug validation. Drug Discovery Today 2016;21:1553-60. [DOI: 10.1016/j.drudis.2016.06.024] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 9.5] [Reference Citation Analysis]
199 Ko H, Kim Y. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer. Arch Pharm Res 2016;39:1597-608. [DOI: 10.1007/s12272-016-0822-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
200 Hashemzaei M, Barani AK, Iranshahi M, Rezaee R, Tsarouhas K, Tsatsakis AM, Wilks MF, Tabrizian K. Effects of resveratrol on carbon monoxide-induced cardiotoxicity in rats. Environ Toxicol Pharmacol 2016;46:110-5. [PMID: 27458698 DOI: 10.1016/j.etap.2016.07.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
201 Lapierre JM, Eathiraj S, Vensel D, Liu Y, Bull CO, Cornell-Kennon S, Iimura S, Kelleher EW, Kizer DE, Koerner S, Makhija S, Matsuda A, Moussa M, Namdev N, Savage RE, Szwaya J, Volckova E, Westlund N, Wu H, Schwartz B. Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. J Med Chem 2016;59:6455-69. [PMID: 27305487 DOI: 10.1021/acs.jmedchem.6b00619] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 6.7] [Reference Citation Analysis]
202 Lu X, Liu Y, Luo F, Zhang A, Liu X, Lu L, Shi L, Li J, Xue J, Xu H, Fan W, Liu Q. MicroRNA-21 activation of Akt via PTEN is involved in the epithelial-mesenchymal transition and malignant transformation of human keratinocytes induced by arsenite. Toxicol Res (Camb) 2016;5:1140-7. [PMID: 30090420 DOI: 10.1039/c6tx00041j] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
203 Pennisi M, Russo G, Di Salvatore V, Candido S, Libra M, Pappalardo F. Computational modeling in melanoma for novel drug discovery. Expert Opin Drug Discov 2016;11:609-21. [PMID: 27046143 DOI: 10.1080/17460441.2016.1174688] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]